| Cas No.: | 75530-68-6 |
| Synonyms: | FK235;Escor;FR34235;Nivadil;Nivadip |
| SMILES: | COC(C1=C(C#N)NC(C)=C(C(OC(C)C)=O)C1C2=CC([N+]([O-])=O)=CC=C2)=O |
| Formula: | C19H19N3O6 |
| M.Wt: | 385.3707 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Nilvadipine(FR34235) is a calcium channel blocker for treatment of hypertension. Nilvadipine is a new calcium antagonist of the the dihydropyridine group. Nilvadipine is mainly excreted via the kidneys in the form of inactive metabolites. Nilvadipine can be used to treat hypertensive patients who are also suffering from diabetes mellitus, lipometabolic disturbances, chronic obstructive respiratory tract disease, or cerebral circulatory disturbances. Owing to its high vascular selectivity, antiatherogenic properties, 24-h action, and good tolerance, nilvadipine fulfills the requirements for a modern antihypertensive agent. FR34235 was also the most potent among the calcium antagonists tested. The IC50 values were 3.3 × 10?11 M for FR34235. FR34235 should be useful for preventing and treating atherosclerosis. Inhibition of smooth muscle cell migration is thought to be its mechanism of antiatherogenic activity. The apparent half-maximum inhibitory concentrations (IC50s) at every 1- and 30-s stimulation were 1.9×10?6 M and 7.6×10?6 M for nilvadipine, respectively. Nilvadipine selectively inhibited the L-type Ca2+ channel current which comprised 34% of the total HVA ICa. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
